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http://www.lipidworld.com/content/12/1/7RESEARCH Open AccessAdipose tissue arachidonic acid content is
associated with the expression of 5-lipoxygenase
in atherosclerotic plaques
Michael S Nielsen1*, Marie-Louise M Grønholdt2, Mogens Vyberg3, Kim Overvad1,4, Annette Andreasen1,
Karen-Margrete Due1 and Erik B Schmidt1Abstract
Background: The content of arachidonic acid in adipose tissue is positively associated with the risk of myocardial
infarction, whereas the content of eicosapentaenoic acid in adipose tissue has been reported to be negatively
associated with the risk of myocardial infarction. Both arachidonic acid and eicosapentaenoic acid are substrates for
the synthesis of pro-inflammatory leukotrienes and leukotrienes derived from eicosapentaenoic acid are generally
much less potent. In this study we hypothesized that a high content of arachidonic acid in adipose tissue would
reflect a high formation of arachidonic acid derived leukotrienes and a high expression of 5-lipoxygenase in
atherosclerotic plaques. Likewise, we hypothesized that a high content of eicosapentaenoic acid in adipose tissue
would reflect a low formation of arachidonic acid derived leukotrienes and a low expression of 5-lipoxygenase in
plaques.
Methods: In a cross sectional study we included 45 consecutive subjects undergoing femoral
thrombendarterectomy. The expression of 5-lipoxygenase in plaques was assessed by a semi-automated image
analysis computer programme after immunohistochemical staining with mono-clonal 5-lipoxygenase antibodies.
Leukotriene B4 and cysteinyl leukotriene formation from stimulated femoral artery plaques was quantified using
ELISA methods. The fatty acid content of adipose tissue biopsies from the thigh was analyzed using gas
chromatography. Associations between variables were assessed by Pearson correlations and were further explored
in a multivariable linear regression model adjusting for potential confounders.
Results: A high content of arachidonic acid in adipose tissue was associated with a higher expression of
5-lipoxygenase in plaques (r = 0.32, p = 0.03), but no significant associations with leukotriene B4 (r = 0.22, p = 0.14)
and cysteinyl leukotriene (r = −0.11, p = 0.46) formation was seen. No significant associations were found between
the content of eicosapentaenoic acid in adipose tissue and 5-lipoxygenase expression or leukotriene formation in
plaque.
Conclusions: Adipose tissue arachidonic acid contents correlated positively with the expression of 5-lipoxygenase
in plaques. This association might represent a causal link between adipose tissue arachidonic acid and the risk of
myocardial infarction but confirmatory studies are needed.
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The marine omega-3 polyunsaturated fatty acid (PUFA),
eicosapentaenoic acid (EPA) is generally considered to
be beneficial in the prevention of coronary artery disease
[1] whereas the n-6 PUFA, arachidonic acid (ARA), has
been linked to a higher risk [2-4]. Both ARA and EPA
serve as substrates for 5-lipoxygenase, the initiating en-
zyme in the biosynthesis of pro-inflammatory leukotrienes
(Figure 1) and as described below, the leukotrienes derived
from EPA are generally much less potent as compared to
those derived from ARA. The ARA-derived leukotrienes
have been linked to the development of atherosclerosis
and plaque instability via increased leukocyte chemotaxis,
vascular inflammation and subsequent matrix degener-
ation [5]. Leukotriene B4 (LTB4) is one of the most potent
chemotactic agents known to date, and the cysteinyl leu-
kotrienes (LTC4, LTD4 and LTE4) are powerful spasmo-
genic agents in asthma. ARA is the natural precursor of
the above mentioned 4-series (i.e. 4 double bonds) leuko-
trienes formed in activated leukocytes, including macro-
phages. On the other hand, EPA can act as an alternative
substrate, leading to the formation of 5-series leukotrienes
(LTB5, LTC5, LTD5, LTE5) of which LTB5 is at least 30
times less potent in chemoattractant and aggregating
properties compared to the ARA-derived LTB4 [6]. The
cysteinyl leukotrienes, however, seem to possess equally
potent biological activities regardless of the number of
double bonds [7,8].
Adipose tissue is widely used in epidemiological stud-
ies as a biomarker of long term intake of PUFA [9]. A
high adipose tissue content of marine omega-3 PUFA
has been associated with a lower risk of acute coronary
syndrome [10,11], while on the contrary, a high content
of ARA in adipose tissue has been associated with aLeukotriene A4
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Figure 1 Formation of leukotrienes from arachidonic acid and eicosap
leukotrienes derived from arachidonic acid (ARA). The initial step is catalyze
enzyme availability of the individual cell, either leukotriene B4 or leukotrien
to leukotriene D4 and then to leukotriene E4, and these leukotrienes are co
synthesis of 5-series leukotrienes derived from eicosapentaenoic acid (EPA)
double bond, it serves as a co-substrate for the enzymes used for the formhigher risk of myocardial infarction [2-4]. The mechanis-
tic explanation of these findings is unsettled, but impacts
on plaque inflammation and thus plaque stability could
be an important factor. In the present study, we
hypothesized that the content of EPA in adipose tissue
reflect lower levels of 5-lipoxygenase and 4-series leuko-
trienes in femoral atherosclerotic plaques, and that the
content of ARA in adipose tissue, on the other hand, is
associated with higher levels of 4-series leukotrienes and
5-lipoxygenase in plaques. Since EPA and ARA in adi-
pose tissue must be liberated into the circulation and
probably also incorporated into atherosclerotic plaques
in order to affect the lipoxygenase pathway in the arter-
ial wall, our secondary aim was to assess the correlation
between the content of these fatty acids in adipose
tissue, plasma, and atherosclerotic femoral plaques,
respectively.Results
Subject characteristics
Fifty subjects undergoing femoral thrombendarterect-
omy were included in the study but five subjects were
later withdrawn from the study due to delays in surgery,
caused by non-study related medical emergencies in
other patients. These delays entailed logistic problems,
for which reason atherosclerotic plaques and/or blood
samples were not collected for this study from these five
patients. Subject characteristics are given in Table 1. The
median age of the 45 subjects included in the final ana-
lysis was 71 years, and both sexes were equally repre-
sented (53% males). More than half (58%) had
symptomatic atherosclerotic disease from more than one
arterial vascular bed. The median intake of marine5-lipoxygenase
+ FLAP
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B
entaenoic acid. To the left is seen the synthesis of 4-series
d by 5-lipoxygenase and leukotriene A4 is formed. Next, depending on
e C4 will be formed. If leukotriene C4 is formed, it is quickly converted
llectively known as cysteinyl leukotrienes. To the right is seen the
. Since EPA is chemically identical to ARA, apart from one additional
ation of 4-series leukotrienes (competitive inhibitor).
Table 1 Baseline characteristics
Variable Value
Age*, years 71 (54 – 81)
Sex (% men) 53
Body mass index*, kg/m2 25 (18 – 30)
EPA + DHA intake* (g/day) 0.68 (0.16 – 1.69)
Current smokers, % 33
Medical history and medications
Cardiovascular disease†, % 58
Diabetes mellitus, % 24
Aspirin treatment, % 98
Anti-hypertensive medication, % 78
Statin treatment, % 96
NSAID use‡, % 7
Laboratory examination
Total cholesterol*, mmol/l 3.8 (3.1 – 4.6)
P-glucose*, mmol/l 5.9 (5.3 – 8.7)
P-hsCRP§, mg/l (n = 37)e 1.8 (0.3 – 6.4)
P-creatinine*, μmol/l 85 (56 – 107)
* Median (10th and 90th percentiles).
† Any diagnosis of stable angina, unstable angina, MI, ischemic stroke,
transitory ischemic attack or any procedure of percutaneus coronary
intervention or coronary artery bypass grafting.
‡ Chronic use of non-steroidal anti-inflammatory drugs (NSAID).
§ Subjects with hsCRP > 10 mmol/l (n = 8) were omitted since these values
suggest acute rather than low-grade inflammation.
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0.68 g/day.
Plaque characteristics
Atherosclerotic plaques were all advanced lesions. They
were generally highly fibrotic and heavily calcified and
71% were without any lipid core. Inflammatory cells
were present in very low numbers. The median expres-
sion of 5-lipoxygenase in the plaques was 0.19% and
median LTB4 and cysteinyl leukotriene formation from
stimulated plaques were 3.4 ng/g and 7.3 ng/g, respect-
ively. A statistically significant correlation between
5-lipoxygenase expression and LTB4 formation (r = 0.32,
95% CI: 0.03; 0.56, p = 0.03), but not cysteinyl leuko-
triene formation (r = 0.06, 95% CI: -0.24; 0.35, p = 0.71),
was observed.
Associations between the content of ARA and EPA in
adipose tissue and the expression of 5-lipoxygenase and
formation of leukotrienes in plaques
Adipose tissue ARA was positively correlated with both
the expression of 5-lipoxygenase in plaques (r = 0.32)
and the formation of LTB4 in plaques, (r = 0.22), al-
though the latter was not statistically significant
(Table 2). No significant association between adipose tis-
sue ARA content and formation cysteinyl leukotrienes inplaques were observed. The content of EPA in adipose
tissue was positively, but not significantly, correlated
with expression of 5-lipoxygenase (r = 0.14), forma-
tion of LTB4 (r = 0.25), and formation of cysteinyl leuko-
trienes (r = 0.02). Neither the content of ARA nor the
content of EPA in adipose tissue was significantly corre-
lated with LTE4 levels in urine (a marker of total
body cysteinyl leukotriene formation). The association
between the content of ARA in adipose tissue and 5-
lipoxygenase was further explored in a linear regression
model, mainly to elucidate whether adjustment for age,
sex, and BMI would change the conclusions. In the
crude model, the regression coefficient for the associ-
ation between the content of ARA in adipose tissue and
5-lipoxygenase expression in plaque was 0.35% (95% CI:
0.06; 0.64, p = 0.019) and the regression coefficient was
0.47% (95% CI: 0.16; 0.78, p = 0.004) after adjustment for
age, sex and BMI. No statistically significant associations
were found in any of the other linear regression analyses,
and adjustment for age, sex, and BMI (data not shown)
did not change any of the conclusions already obtained
from the correlation analyses.
Associations between the content of linoleic acid and
docosahexaenoic acid in adipose tissue and the
expression of 5-lipoxygenase and formation of
leukotrienes in plaques
Since both linoleic acid and docosahexaenoic acid could
indirectly affect the content of ARA and EPA in adipose
tissue and plaques, we included these PUFA in an explora-
tory analysis. No substantial nor statistically significant
correlations were observed between the content of doco-
sahexaenoic acid in adipose tissue and 5-lipoxygenase ex-
pression in plaque (r = 0.04, 95% CI: -0.26; 0.33, p = 0.80),
LTB4 in plaques (r = 0.18, 95% CI: -0.12; 0.45, p = 0.23),
cysteinyl leukotrienes in plaques (r = 0.01, 95% CI: -0.28;
0.30, p = 0.96) or urine LTE4 levels (r = −0.04, 95%
CI: -0.34; 0.25, p = 0.75). Likewise, the content of linoleic
acid in adipose tissue was neither substantially nor statisti-
cally significantly correlated with 5-lipoxygenase expres-
sion in plaque (r = −0.06, 95% CI: -0.35; 0.24, p = 0.70),
LTB4 in plaques (r = −0.09, 95% CI: -0.37; 0.21, p = 0.55),
cysteinyl leukotrienes in plaques (r = 0.09, 95% CI: -0.21;
0.37, p = 0.57), or urine LTE4 levels (r = −0.05, 95%
CI: -0.34; 0.25, p = 0.73).
Correlations between the content of EPA and ARA in
adipose tissue, plasma, and atherosclerotic plaques
The median content of ARA and EPA was 0.34% and
0.09% in adipose tissue, 10.74% and 1.91% in plasma
phospholipids, and 6.45% and 0.81% in plaque tissue. As
can be seen from Figure 2, we observed statistically sig-
nificant positive correlations, both between ARA in adi-
pose tissue and ARA in plasma phospholipids, and
Table 2 Correlations between PUFA content in adipose tissue and 5-lipoxygenase pathway constituents in plaque
and urine
Adipose tissue arachidonic acid
(% of total fatty acids)
Adipose tissue eicosapentaenoic acid
(% of total fatty acids)
r 95% CI p r 95% CI p
Plaque
5-lipoxygenase expression (% of plaque area) 0.32 0.03 to 0.56 0.03 0.14 −0.16 to 0.41 0.37
Leukotriene B4 (ng/g) 0.22 −0.08 to 0.42 0.14 0.25 −0.05 to 0.50 0.10
Cysteinyl leukotrienes (ng/g) −0.11 −0.39 to 0.19 0.46 0.02 −0.27 to 0.31 0.87
Urine
Leukotriene E4 (pg/mg creatinine) 0.02 −0.28 to 0.31 0.92 −0.12 −0.40 to 0.18 0.44
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ques. ARA in adipose tissue and ARA in plaques did not
correlate. The contents of EPA in adipose tissue, plasma
phospholipids, and plaques were all positively correlated
with statistically significant coefficients of correlation be-
tween all compartments.
Discussion
In this study, we analyzed the content of EPA and ARA
in adipose tissue biopsies from subjects with peripheral
artery disease and evaluated whether these fatty acids
were associated with the expression of 5-lipoxygenase as
well as the formation of LTB4 and cysteinyl leukotrienes
in femoral plaques. Furthermore, we measured the con-
tent of ARA and EPA in both plasma and plaques in
order to establish a possible biological pathway in which
the content of ARA and EPA in adipose tissue could
affect the 5-lipoxygenase pathway in the arterial wall.
Our major finding, was a statistically significant associ-
ation between the content of ARA in adipose tissue and
the expression of 5-lipoxygenase in atherosclerotic pla-
ques, which persisted after adjustment for age, sex, and
BMI. We also observed a weak positive correlation be-
tween adipose tissue ARA contents and LTB4 formationAdipose tissue AA
r = 0.41 (0.13; 0.63), p = 0.005
r = 0.08 (-0.22; 0.
Plasma phosph
Adipose tissue EPA Plasma phos
EPA
r = 0.66 (0.46; 0.80), p < 0.001
r = 0.51 (0.26; 0.7
Figure 2 Schematic of the correlations between adipose tissue, plasm
eicosapentaenoic acid. A: Positive correlations were found between the c
phospholipids as well as between plasma phospholipids and atherosclerot
adipose tissue and plaque was observed. B: Strong positive correlations be
compartments were found indicating that EPA is readily incorporated intoin plaques which, however, did not reach statistical
significance (p = 0.14). Other investigators have previously
assessed the expression of 5-lipoxygenase in atheroscler-
otic plaques [12-16] although none of them assessed fem-
oral artery plaques. Two recent studies [13,15] have linked
both 5-lipoxygenase expression and LTB4 formation to ca-
rotid plaque instability by reporting higher levels in un-
stable compared to stable plaques, as assessed by the
presence of recent neurological symptoms. Other results
supporting these findings were reported by Zhou et al.
[12] who found that 5-lipoxygenase expression and LTB4
formation in carotid plaques were higher in diabetic com-
pared to non-diabetic patients and by Spanbroek et al.
[14] who found that 5-lipoxygenase expression was higher
in more advanced atherosclerotic lesions. Although asso-
ciations between the content of ARA and EPA in adipose
tissue and 5-lipoxygenase pathway constituents in plaques
have not been assessed previously, some indirect evidence
for such an association has been derived from genetic
studies. Dwyer et al. [17] thus reported that homozygous
carriers of a short tandem repeat polymorphism in the
promoter region of the gene encoding 5-lipoxygenase
were significantly associated with a higher carotid intima-
media thickness. This association was stronger forr = 0.33 (0.04; 0.57), p = 0.03
37), p = 0.63
olipid AA Femoral plaque AA
pholipid Femoral plaque EPA
r = 0.65 (0.44; 0.79), p < 0.001
0), p < 0.001
a phospholipid and plaque content of arachidonic acid and
ontent of arachidonic acid (ARA) in adipose tissue and plasma
ic plaques. No significant correlation between the content of ARA in
tween the content of eicosapentaenoic acid (EPA) in all three
all these compartments.
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for individuals with high dietary intake of marine omega-3
polyunsaturated fatty acids. In another genetic association
study, Allayee et al. [18] was, however, unable to demon-
strate an association between the same promoter poly-
morphism and the risk of myocardial infarction. However,
subjects with high intakes of ARA had a significantly
higher risk (OR = 1.32) of myocardial infarction compared
to subjects with low ARA intakes (OR = 0.80). No gene-
diet interaction was found for omega-3 fatty acids. In the
present study, the finding of a positive association between
the content of ARA in adipose tissue and the expression of
5-lipoxygenase in plaques is in line with the results of these
nutrigenomic studies and thus provides further evidence
for the importance of this fatty acid on the 5-lipoxygenase
pathway. All together, these findings strengthen the hy-
pothesis that the positive association between adipose
tissue ARA and the risk of myocardial infarction [2-4]
reported in epidemiological studies could be causal, at least
partly, through higher expression of 5-lipoxygenase in the
arterial wall.
Adipose tissue ARA was not correlated with either cystei-
nyl leukotriene formation in plaque or total body cysteinyl
leukotriene formation, of which the latter can be estimated
from urinary LTE4 levels [19]. While evidence for a link be-
tween LTB4 and plaque instability is supported by quite con-
cordant results from several studies, the role of cysteinyl
leukotrienes in plaque biology is more ambiguous. Qiu et al.
[15] found a positive correlation between plaque instability
and mRNA levels of the enzymes used for LTB4 synthesis
(5-lipoxygenase, 5-lipoxygenase activating protein, LTA4
hydrolase) but not for cysteinyl leukotriene synthesis (LTC4
synthase). On the other hand, urinary LTE4 levels have been
reported to be significantly higher in patients suffering from
acute coronary syndrome compared to controls [20], and
cysteinyl leukotrienes have been shown to be capable of in-
ducing coronary spasm in ex vivo atherosclerotic coronary
arteries but not in normal arteries [16]. Based on the results
from the present study one could speculate that advanced
femoral atherosclerotic plaques have a low expression of
LTC4 synthase since 5-lipoxygenase expression was not sig-
nificantly correlated to cysteinyl leukotriene levels in stimu-
lated plaques.
We expected the content of EPA in adipose tissue to be
associated with lower levels of leukotriene formation and
5-lipoxygenase expression in plaques, since dietary supple-
mentation with fish oil (EPA+DHA) has been associated
with increased stability of carotid plaques [21]. Furthermore,
the content of EPA in plaques was associated with more
stable and less inflammatory plaques [22]. Despite high cor-
relations between EPA levels in adipose tissue, plasma phos-
pholipids, and atherosclerotic plaques, suggesting a high
degree of incorporation of dietary EPA into all these com-
partments, we actually found positive correlations betweenthe content of EPA in adipose tissue and 5-lipoxygenase
expression as well as LTB4 and cysteinyl leukotriene for-
mation in plaques. These correlations were, however,
non-significant, and hence no “harmful” association was
detected per se, but surely, this study does not suggest any
clinically beneficial association between EPA and the for-
mation of 5-lipoxygenase products in femoral plaques. In a
supplementary exploratory analysis, we determined correl-
ation between the content of linoleic acid and docosahexae-
noic acid in adipose tissue and 5-lipoxygenase expression
and leukotriene formation in plaques, since these PUFA
could potentially affect leukotriene formation in plaques.
However, no significant correlations were observed.
In order to causally affect the 5-lipoxygenase pathway in
the arterial wall, adipose tissue should be able to deliver
increased amounts of ARA into the circulation and prob-
ably also onward into the arterial wall. This mechanism
seems plausible, since ARA (and EPA) is far more likely to
be liberated from adipose tissue compared to other fatty
acids [23] indicating that even small differences in the con-
tent of these PUFA in adipose tissue could be clinically
relevant. In the present study we found evidence that adi-
pose tissue ARA is highly correlated with circulating ARA
in plasma phospholipids (Figure 3). It should be acknowl-
edged that fatty acids is released from adipose tissue as free
fatty acids and not as phospholipids, however a previous
study suggested that free ARA (non-esterified) in plasma is
highly correlated with plasma ARA contents in phospholi-
pids [24]. The content of ARA in plasma phospholipid was
also correlated with the content of ARA in plaque, which
makes it plausible that ARA originating from the adipose
tissue could be incorporated into the arterial wall. How-
ever, no direct correlation was seen between the content of
ARA in adipose tissue and the content of ARA in plaques
in this study. This lack of correlation could be due to
somewhat imprecise measurements of ARA in plaques
(Coefficient of variation (CV) = 26%).
Several weaknesses of this study should be acknowl-
edged. The selection of study tissue is open for discus-
sion. We looked at femoral artery plaques which were in
a chronic stage of fibrosis, calcification, and most often
without any lipid core which is in contrast to carotid
plaques [25]. The grade of inflammation in femoral pla-
ques was lower than expected, making it harder to de-
tect correlations between adipose tissue fatty acids and
leukotriene formation/5-lipoxygenase expression in pla-
ques. Furthermore, the extensive calcification in these
plaques sometimes made them fall apart when they were
dissected prior to stimulation. Only, coherent plaque tis-
sue was weighed and stimulated (since calcium crystals
would be inactive tissue), which could have introduced
imprecision in the assessment of leukotriene formation
from stimulated plaques, since they were expressed as
ng leukotriene/g plaque. Furthermore, the formation of
Figure 3 Quantification of 5-lipoxygenase expression in plaques. A: The section of the plaque is automatically outlined as the region of
interest. B: Immunostaining of the plaque with monoclonal rabbit 5-lipoxygenase antibodies (zoom x 200). C: Automated detection of the
stained areas using image analysis application software developed for 5-lipoxygenase staining.
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stimulation of plaques, which makes clinical interpret-
ation of results more complex. Residual confounding
cannot be excluded, since the size of the study only
allowed us to include three potential confounders (age,
sex, and BMI) in the multiple linear regression analyses.
The main strength of the study is the accurate and re-
producible assessment of the exposures of interest (adi-
pose tissue ARA and EPA) and of 5-lipoxygenase
expression in plaques.
Conclusions
We found a positive association between the content
of ARA in adipose tissue and the expression of
5-lipoxygenase in femoral atherosclerotic plaques, but
no significant correlation with leukotriene formation
was seen. The content of EPA in adipose was not signifi-
cantly correlated with any of the 5-lipoxygenase pathway
constituents. Both the ARA and the EPA content in adi-
pose tissue was significantly positively correlated with
their respective PUFA in plasma phospholipids, which
again was correlated with the respective PUFA in pla-
ques. This study provides evidence for a possible bio-
logical link between the content of ARA in adipose
tissue and coronary heart disease. However, confirma-
tory studies assessing the association between the
content of ARA in adipose tissue and the expression of
5-lipoxygenase pathway constituents in more inflamma-
tory plaques (i.e. carotid artery) should be undertaken in
order to explore this hypothesis further.
Methods
Subjects and design
In a cross sectional design, we included fifty consecutive
subjects scheduled for femoral artery thrombendarter-
ectomy due to symptomatic peripheral artery disease.The inclusion criteria were: age > 18 years and a diagno-
sis of peripheral artery disease with planned femoral
thrombendarterectomy. Exclusion criteria were any one
of the following: allergic asthma or rhinitis, any chronic
inflammatory disease, systemic steroid treatment, cancer,
acute coronary syndrome within the last 30 days, and in-
ability to give informed consent. Patient history, medica-
tion, vital parameters, and food frequency questionnaires
were recorded at admission, while blood and urine sam-
ples were obtained in the fasting state on the day of sur-
gery. Atherosclerotic femoral artery plaques as well as
adipose tissue biopsies from the subcutis of the thigh
were collected during surgery. Approval of the study was
obtained from the regional research ethics committee
(N-20100047), and all patients gave informed consent.
Analysis of atherosclerotic plaques
During femoral artery thrombendarterectomy, plaques
were removed and placed in isotonic saline and im-
mediately brought to the research laboratory together
with the adipose tissue biopsy. Two small pieces of
the plaque were cut off. The first piece was used for
the analysis of leukotriene formation, while the other
piece was used for analysing the content of ARA and
EPA. The remaining part of the plaque was fixed in
formalin followed by decalcification in formic acid.
Cross-sectioning of the plaque was performed at
3 mm intervals, and the resulting blocks were embedded
in paraffin. From each block one 3 μm section was cut
and stained with hematoxylin and eosin. An experienced
consultant pathologist (MV) identified the histological
section with the largest plaque area (culprit lesion) and
did a descriptive histological evaluation of the athero-
sclerotic lesion in this section. Then, new 3 μm sections
from this block and the two neighboring blocks were
cut. We chose this area of the plaque since this is
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three sections were immunostained for 5-lipoxygenase,
using anti-5-lipoxygenase monoclonal rabbit antibody
clone C49G1 (Cell Signaling Technology, Inc. USA). An
irrelevant monoclonal rabbit antibody in the same con-
centration as the 5-lipoxygenase antibody was applied as
negative control on representative slides and showed no
staining reaction. For image acquisition (Figure 3), the
immunostained slides were scanned on a nanozoomer
HT 1.0 (Hamamatsu, Japan) with the 40× source lens
setting and then loaded into image analysis application
software developed for 5-lipoxygenase staining (Visio-
pharm, Denmark). The percentage of the plaque area
occupied by 5-lipoxygenase for each section was then
calculated automatically by the computer software and
the average staining fraction from the three sections
was used as the primary outcome. The intra-observer
CV was 0% based on a re-evaluation of ten sections
after 3 months.
The piece of plaque used for leukotriene analysis was
cut into smaller pieces and put into stimulation vials.
After stimulation with calcium ionophore A23187 the
levels of LTB4 (R&D Systems, Minneapolis, USA) and
cysteinyl leukotrienes (Enzo Life Sciences Inc, New
York, USA) were quantified using solid phase immuno-
assay ELISA kits with a competitive technique. To adjust
for inter-individual differences in the amount of plaque
tissue, the levels of leukotrienes were expressed as ng/g
plaque tissue. The intraserial CV was 5% for LTB4 and
4% for cysteinyl leukotriene measurements.
Lipids of the plaque were extracted according to Folch
et al. [28] and the fatty acid composition was analyzed
by gas chromatography as earlier described [11]. The
content of ARA and EPA was expressed as percent of
total fatty acids and the intraserial CV was 26% for both
fatty acids.
Analysis of the content of PUFA in adipose tissue
Adipose tissue biopsies from the subcutis of the thigh
were obtained during surgery and placed in dry vials.
Approximately 2–4 mg was analyzed for the content of
individual PUFA using gas chromatography and the
intraserial CV was 4% for ARA and 8% for EPA.
Analysis of the content of PUFA in plasma phospholipids
Fasting blood samples were collected from all patients
on the day of surgery. In the assessment of the individ-
ual fatty acid contents in plasma phospholipids, total
lipids were extracted from plasma according to Folch
et al. [28]. Separation of fatty acids from plasma phos-
pholipids was done according to Burdge et al. [29]. The
fatty acid composition was analysed by gas chromatog-
raphy and the intraserial CV was 1% for ARA and 2%
for EPA.Leukotriene E4 in urine
Quantification of urine LTE4 levels was done using a
solid phase immunoassay ELISA kit (USCN life science
Inc, Wuhan, China) and the intraserial CV was 17%.Statistics
We used Pearson’s product–moment coefficient of correl-
ation model to explore associations between our expo-
sures (adipose tissue EPA and ARA) and the primary
outcomes (5-lipoxygenase, LTB4, cysteinyl leukotrienes in
plaques) and secondary outcomes (urinary LTE4 levels,
EPA and ARA in plasma phospholipids, EPA and ARA in
plaques). We further explored associations with our pri-
mary outcomes using multivariable linear regression mod-
els, in which we included the following a priori selected
potential confounders: Age (continuous), sex (dichotom-
ous), and BMI (continuous). In exploratory analyses, we
also evaluated adipose tissue linoleic acid and docosahex-
aenoic acid as exposure variables. The distributions of
most of the variables were positively skewed, and logarith-
mic transformation was therefore applied when appropri-
ate. Assumptions of normality, linear relationship, and
equal variances were found to be satisfactory when
assessed by relevant graphical plots. Statistical tests were
two-tailed, and P < 0.05 was considered significant. The
STATA 11 software package (Stata Corp., College Station,
TX, US) was used for all analyses.
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